This study will test the long-term safety of a drug called **buntanetap** for people with **Parkinson's Disease (PD)**. Parkinson's Disease is a disorder that affects movement and causes tremors. The study lasts for 36 months (3 years) and includes two groups of participants, called cohorts. Cohort 1 will include people who have tried buntanetap in past studies. Cohort 2 will include those receiving **Deep Brain Stimulation (DBS)**, a treatment using electrical signals to help control movement. Each participant will take 30mg of buntanetap once a day. Before joining, participants will have a health check-up, which can take up to 42 days. During the study, some tests like MMSE (Mini-Mental State Examination) and MoCA (Montreal Cognitive Assessment) will be done to check brain function. Participants may have to stop certain Parkinson's medications for a short time before clinic visits.

• The study lasts for 3 years with regular check-ups.
• Buntanetap dosing is 30mg daily.
• Participants might need to pause some medications temporarily.